Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Sanofi SA — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.66, while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA pays a 5.53% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals.
| RDTE | SNY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $34.72 | $52.34 |
52-Week Low | $26.40 | $41.33 |
Market Cap | — | $104.85B |
Enterprise Value | — | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE stock trades at $28.57, down 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company has announced multiple small dividends for 2026, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about the fund's strategy and capital erosion risks.
The outlook is cautious due to structural risks in the covered call strategy capping upside and exposing downside, as noted by Seeking Alpha. Investment opportunity hinges on income from dividends, but risks of NAV deterioration and negative media sentiment present significant headwinds for shareholders.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
